Immunogenicity of an Escherichia coli-Produced Recombinant 9-Valent Human Papillomavirus Vaccine in Mice and Rats
Vaccines · 01.05.2026 · 14 (5) · 407
DOI: 10.3390/vaccines14050407 ↗Kurz gefasst
Fachartikel in der Zeitschrift Vaccines, online erschienen am 01.05.2026. Verfasst von Yu-Ying Liu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Beijing Health Guard Biotechnology Inc., Beijing 100176, China. Die Arbeit nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Prophylactic human papillomavirus (HPV) vaccines are crucial for preventing HPV-related cancers. This study aimed to preclinically evaluate a novel recombinant 9-valent HPV vaccine produced in Escherichia coli (E. coli), which targets HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58, and is based on virus-like particles (VLPs) of the HPV major capsid protein L1.
Methods
The molecular weight and purity of HPV L1 protein bands were assessed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) with Coomassie Brilliant Blue staining. The morphology and size distribution of VLPs were characterized using cryo-electron microscopy and DLS. The immunogenicity and durability of the recombinant 9-valent HPV vaccine were evaluated in BALB/c mice and Wistar rats. Mice received single or triple immunizations (2-week intervals) of two vaccine batches or Gardasil®9 (MSD, USA) control at 1/20 human dose. Antibody responses were monitored via ELISA and pseudovirus neutralization assays over 24 weeks. Rats were administered single or triple immunizations (2-week intervals) of high- (1/10), medium- (1/20), or low-dose (1/40) vaccine or Gardasil®9 control (1/20), with neutralizing antibodies tracked for 16 weeks.
Results
Cryo-electron microscopy and DLS revealed that VLPs of each type appeared as uniformly distributed, spherical or ellipsoidal hollow intact particles with a diameter of approximately 45–65 nm. This vaccine demonstrated robust immunogenicity and long-lasting efficacy in BALB/c mice and Wistar rats, with effects comparable to those of the commercially available vaccine Gardasil®9.
Conclusions
The 9-valent HPV vaccine induces robust and persistent immune responses in mice and rats, strongly supporting further clinical trials. It is expected to be an alternative to marketed vaccines and ease the global supply shortage of 9-valent HPV vaccines.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Beijing Health Guard Biotechnology Inc., Beijing 100176, China.
ORCID-Profile: Yu-Ying Liu, Hai-Jiang Zhang
Zitieren
APA
Liu, Y. Y., Yin, F., Li, W. J., Chen, D., Wu, S. M., Chen, X., Wang, Y., Yang, Z. M., Zhang, H. J., & Liu, Y. J. (2026). Immunogenicity of an Escherichia coli-Produced Recombinant 9-Valent Human Papillomavirus Vaccine in Mice and Rats. Vaccines, 14(5), 407. https://doi.org/10.3390/vaccines14050407
Vancouver
Liu YY, Yin F, Li WJ, Chen D, Wu SM, Chen X, et al. Immunogenicity of an Escherichia coli-Produced Recombinant 9-Valent Human Papillomavirus Vaccine in Mice and Rats. Vaccines. 2026;14(5):407. doi:10.3390/vaccines14050407
BibTeX
@article{Liu2026,
author = {Liu, Yu-Ying and Yin, Fei and Li, Wen-Juan and Chen, Dan and Wu, Shu-Ming and Chen, Xiao and Wang, Yan and Yang, Zeng-Min and Zhang, Hai-Jiang and Liu, Yong-Jiang},
title = {Immunogenicity of an Escherichia coli-Produced Recombinant 9-Valent Human Papillomavirus Vaccine in Mice and Rats},
journal = {Vaccines},
year = {2026},
volume = {14},
number = {5},
pages = {407},
doi = {10.3390/vaccines14050407}
}
EUVIMED